Bihua Han

767 total citations · 2 hit papers
11 papers, 453 citations indexed

About

Bihua Han is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Bihua Han has authored 11 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 4 papers in Epidemiology and 4 papers in Hepatology. Recurrent topics in Bihua Han's work include SARS-CoV-2 and COVID-19 Research (5 papers), Hepatitis B Virus Studies (4 papers) and Hepatitis C virus research (4 papers). Bihua Han is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (5 papers), Hepatitis B Virus Studies (4 papers) and Hepatitis C virus research (4 papers). Bihua Han collaborates with scholars based in China, Belarus and South Korea. Bihua Han's co-authors include Zhiwei Wu, Yuliang Zhao, Lei Wang, Minjie Li, Qi Li, Changgui Li, Xiaojuan Lian, Qun Shu, Zhiwei Jiang and Yufei Song and has published in prestigious journals such as Nature Communications, The Lancet Infectious Diseases and Chaos Solitons & Fractals.

In The Last Decade

Bihua Han

9 papers receiving 442 citations

Hit Papers

Safety, tolerability, and immunogenicity of an inactivate... 2021 2026 2022 2024 2021 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
    2021 211 citations Bihua Han, Yufei Song et al. The Lancet Infectious Diseases profile →
  2. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
    2021 173 citations Gang Zeng, Qianhui Wu et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bihua Han China 6 389 194 59 55 44 11 453
Donchida Srimuan Thailand 11 296 0.8× 108 0.6× 16 0.3× 71 1.3× 50 1.1× 27 362
Monica Godfrey United States 9 220 0.6× 126 0.6× 44 0.7× 226 4.1× 23 0.5× 11 431
Anat Wieder-Finesod Israel 7 320 0.8× 85 0.4× 78 1.3× 26 0.5× 38 0.9× 12 355
Ali Nizar Latif Qatar 11 364 0.9× 69 0.4× 17 0.3× 60 1.1× 24 0.5× 23 437
Galit Perez Israel 9 466 1.2× 203 1.0× 14 0.2× 42 0.8× 50 1.1× 16 558
Roberto Dias de Oliveira Brazil 10 396 1.0× 167 0.9× 16 0.3× 84 1.5× 37 0.8× 29 476
Julia E. Tubert United States 10 517 1.3× 199 1.0× 26 0.4× 64 1.2× 43 1.0× 18 590
Natthinee Sudhinaraset Thailand 12 312 0.8× 98 0.5× 9 0.2× 28 0.5× 35 0.8× 29 370
Gina S. Lee United States 9 491 1.3× 190 1.0× 19 0.3× 51 0.9× 43 1.0× 14 547
Meagan E. Deming United States 9 486 1.2× 74 0.4× 11 0.2× 97 1.8× 90 2.0× 16 595

Countries citing papers authored by Bihua Han

Since Specialization
Citations

This map shows the geographic impact of Bihua Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bihua Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bihua Han more than expected).

Fields of papers citing papers by Bihua Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bihua Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bihua Han. The network helps show where Bihua Han may publish in the future.

Co-authorship network of co-authors of Bihua Han

This figure shows the co-authorship network connecting the top 25 collaborators of Bihua Han. A scholar is included among the top collaborators of Bihua Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bihua Han. Bihua Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Li, Zhaohui, et al.. (2025). Hypergraph-based brain network switching rate and its application in epilepsy. Chaos Solitons & Fractals. 203. 117653–117653.
2.
Li, Zhaohui, et al.. (2025). Synchronization stability of epileptic brain network with higher-order interactions. Chaos An Interdisciplinary Journal of Nonlinear Science. 35(1). 1 indexed citations
3.
4.
Xin, Qianqian, Qianhui Wu, Xinhua Chen, et al.. (2022). Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nature Communications. 13(1). 3100–3100. 18 indexed citations
5.
Zeng, Gang, Qianhui Wu, Hongxing Pan, et al.. (2021). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases. 22(4). 483–495. 173 indexed citations breakdown →
6.
Han, Bihua, Yufei Song, Changgui Li, et al.. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21(12). 1645–1653. 211 indexed citations breakdown →
7.
8.
Xin, Qianqian, Qianhui Wu, Xinhua Chen, et al.. (2021). Six-Month Follow-Up of a Booster Dose of CoronaVac: Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials. SSRN Electronic Journal. 1 indexed citations
9.
Zhao, Yuliang, Lulu Pan, Yanhong Zhang, et al.. (2020). Immune response to different types of hepatitis B vaccine booster doses 2–32 years after the primary immunization schedule and its influencing factors. International Journal of Infectious Diseases. 93. 62–67. 7 indexed citations
10.
11.
Zhao, Yuliang, Bihua Han, Xinjiang Zhang, et al.. (2019). Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infectious Diseases. 19(1). 482–482. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donchida Srimuan Breakdown of academic impact, for papers by Monica Godfrey Breakdown of academic impact, for papers by Anat Wieder-Finesod Breakdown of academic impact, for papers by Ali Nizar Latif Breakdown of academic impact, for papers by Galit Perez Breakdown of academic impact, for papers by Roberto Dias de Oliveira Breakdown of academic impact, for papers by Julia E. Tubert Breakdown of academic impact, for papers by Natthinee Sudhinaraset Breakdown of academic impact, for papers by Gina S. Lee Breakdown of academic impact, for papers by Meagan E. Deming
Rankless by CCL
2026